Sugi Predict

Sugi Predict / Compounds / SCHEMBL17377231

SCHEMBL17377231

SCHEMBL17377231

CC(C)(C)OC(=O)N1CCc2scc(Br)c2C1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 2/20 0.48
▸ ESR2 Q92731 1/20 0.46
▸ NR1H2 P55055 2/20 0.45
▸ MAPT P10636 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ MKNK1 Q9BUB5 4/20 0.43
▸ MAPK1 P28482 1/20 0.40
▸ FABP4 P15090 1/20 0.39
▸ FABP5 Q01469 1/20 0.39
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ PRKCI P41743 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ UCHL1 P09936 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25363832 0.89 ADORA1 (0.54) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL6421704 0.86 ADORA1 (0.48) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL29978414 0.83 ADORA1 (0.46) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL21669702 0.83 ADORA1 (0.46) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL17798700 0.82 EED (0.49) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL29977848 0.79 ADORA1 (0.45) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL21669697 0.79 ADORA1 (0.56) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL17377058 0.78 ADORA1 (0.51) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL17377126 0.78 ADORA1 (0.51) ADORA1ESR2NR1H2MAPTKDM4E
SCHEMBL9903677 0.78 USP2 (0.44) ADORA1ESR2NR1H2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2025-08-21 — — US disclosed
US-20230120736-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2023-04-20 — — US disclosed
US-20230114718-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2023-04-13 — — US disclosed
WO-2022234470-A1 NOVEL FUSED HETEROCYCLIC COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI PI INDUSTRIES LTD. (IN) 2022-11-10 — — WO disclosed
US-20200338209-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC (US) 2020-10-29 — — US disclosed
US-20200239553-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2020-07-30 — — US disclosed
US-20200147235-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES ABBVIE INC. 2020-05-14 — — US disclosed
US-20190153108-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC. (US) 2019-05-23 — — US disclosed
EP-3469000-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2019-04-17 — — EP disclosed
EP-3468616-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2019-04-17 — — EP disclosed
WO-2017214301-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC. (US) 2017-12-14 — — WO disclosed
EP-3230283-A1 BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME AbbVie Inc. (US) 2017-10-18 — — EP disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 — — US disclosed
EP-3160466-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-05-03 — — EP disclosed
WO-2016094517-A1 BCL-XL INHIBITORY COMPOUNDS AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME ABBVIE INC. (US) 2016-06-16 — — WO disclosed
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same ABBVIE INC. (US) 2016-06-09 — — US disclosed
WO-2015200677-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 — — WO disclosed
WO-2015200677-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239553-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same BCL2, BCL2L10, BAX ADORA1 4666/4885ESR2 2408/4885NR1H2 3081/4885
US-20230114718-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 ADORA1 2774/4885ESR2 632/4885NR1H2 3380/4885
US-20200338209-A1 ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES HRH3, H1-3, CD274 ADORA1 1318/4885ESR2 4499/4885NR1H2 3994/4885
US-20250263491-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 ADORA1 2774/4885ESR2 632/4885NR1H2 3380/4885
US-20230120736-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD99, SLC3A2, CD63 ADORA1 2255/4885ESR2 2420/4885NR1H2 1566/4885
US-20200147235-A1 ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD99, SLC3A2, CD63 ADORA1 2255/4885ESR2 2420/4885NR1H2 1566/4885
US-20160158377-A1 BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same BCL2, BCL2L10, BAX ADORA1 4666/4885ESR2 2408/4885NR1H2 3081/4885
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 ADORA1 2436/4885ESR2 2678/4885NR1H2 914/4885
US-20190153108-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 ADORA1 2774/4885ESR2 632/4885NR1H2 3380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.